EUVIMEDEUVIMED entdecken
Crossref

Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility

Yianni Protopapadakis iD, Hayden Shuster, Austin B Bambach, Sean Fitzgerald, Christian Brayman, Joseph A Ewing, Mary Blumer

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280241273773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Yianni Protopapadakis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Prisma Health Upstate, Greenville, SC, USA. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Osteoporosis, Renal Insufficiency, Chronic, Bone Diseases, Metabolic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proton-pump inhibitor (PPI) use for management of gastroesophageal reflux disease (GERD) consists of a short-duration trial, according to guidelines. Long-term usage is appropriate under certain indications. Literature has increasingly documented an adverse effect profile of PPIs, including kidney disease and bone fragility.

Objective

To investigate the rate of occurrence of osteopenia, osteoporosis, and chronic kidney disease (CKD) in patients using PPI therapy for longer than the recommended trial period of 8 weeks.

Methods

Retrospective cohort analysis of a single-site primary care clinic. Patients aged 18 to 65 years with PPI prescriptions longer than 8 weeks were included. Information regarding PPI prescriptions, demographics, and medical diagnoses was collected.

Results

The search discovered 293 PPI-users and 1908 never-PPI-users. Demographics varied, with a P-value

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsOsteoporosisRenal Insufficiency, ChronicBone Diseases, MetabolicHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedGastroesophageal RefluxYoung AdultAdolescentCohort Studies

Stichwörter der Autor:innen

kidney diseaseomeprazoleosteopeniaosteoporosispantoprazoleproton-pump inhibitors

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Prisma Health Upstate, Greenville, SC, USA.
  • School of Medicine-Greenville, University of South Carolina, Greenville, SC, USA.
  • Department of Research and Biostatistics, Prisma Health Upstate, Greenville, SC, USA.

ORCID-Profile: Yianni Protopapadakis

Zitieren

APA

Protopapadakis, Y., Shuster, H., Bambach, A. B., Fitzgerald, S., Brayman, C., Ewing, J. A., & Blumer, M. (2025). Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241273773

Vancouver

Protopapadakis Y, Shuster H, Bambach AB, Fitzgerald S, Brayman C, Ewing JA, et al. Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241273773

BibTeX
@article{Protopapadakis2025,
  author = {Protopapadakis, Yianni and Shuster, Hayden and Bambach, Austin B and Fitzgerald, Sean and Brayman, Christian and Ewing, Joseph A and Blumer, Mary},
  title = {Effects of Prolonged Proton-Pump Inhibitor Use on Renal Dysfunction and Bone Fragility},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280241273773}
}
Kostenlos starten →